<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918033</url>
  </required_header>
  <id_info>
    <org_study_id>4117-200</org_study_id>
    <secondary_id>132244</secondary_id>
    <nct_id>NCT01918033</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)</brief_title>
  <official_title>A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of desloratadine (MK-4117) in Japanese
      participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine
      is superior to placebo after 2 weeks of treatment with regard to change from baseline in
      Total Nasal Symptom Score among Japanese participants with perennial allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Week 4</time_frame>
    <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who experienced an AE, regardless of causality or severity, was summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to Week 2</time_frame>
    <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who discontinued study drug, whether permanently or temporarily, due to an AE was summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1</measure>
    <time_frame>Baseline and Day 3, Week 1</time_frame>
    <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attackes; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores could range from 0 to 3, with a higher nasal symptom sub-score indicating more frequent/severe nasal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Finding Score Assessed by the Investigator</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>The investigator conducted rhinoscopic examinations on participants to evaluate: swelling of inferior nasal concha mucosa (INCM) (score of 0=none to 3=middle nasal concha is not visible), coloring of inferior nasal concha mucosa (INCM) (score of 0=normal to 3=pale), and nasal discharge production (NDP) (score of 0=none to 3=congesting). The score for each nasal finding component could range from 0 to 3, with a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Symptom Score Assessed by the Investigator</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>The investigator interviewed and examined participants for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator</measure>
    <time_frame>Day 3, Week 1, Week 2</time_frame>
    <description>The investigator comprehensively evaluated participants on global improvement according to 5 grades: 1=remarkably improved, 2= moderately improved, 3=slightly improved, 4=unchanged, and 5=aggravated. The number of participants who were evaluated as remarkably improved and moderately improved was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>The investigator interviewed participants at Baseline, Day 3, Week 1 and Week 2 to evaluate interference with daily activities according to the following scale: 0=none, 1=nasal symptom interferes with daily activities from time to time (+), 2=between 1 and 3 (++), and 3=nasal symtom interferes with daily activity often (+++). Interference with daily activities scores could range from 0 to 3, with a higher score indicating greater interference with daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>Participants evaluated themselves in their daily allergy diaries for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Each nasal symptom sub-score could range from 0 to 3, with a higher sub-score indicating more frequent/severe nasal symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eye Symptom Score Reported in Participant Diaries</measure>
    <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
    <description>Participants evaluated themselves in their daily allergy diaries for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">608</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Desloratadine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desloratadine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine 5 mg</intervention_name>
    <description>Desloratadine 5 mg tablets</description>
    <arm_group_label>Desloratadine 5 mg</arm_group_label>
    <arm_group_label>Desloratadine 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to desloratadine 5 mg tablets</description>
    <arm_group_label>Desloratadine 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with perennial allergic rhinitis

          -  Outpatient.

        Exclusion Criteria:

          -  Lower respiratory tract infection or nasopharyngolaryngeal infection (acute upper
             respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.)

          -  Coexisting infections or systemic mycosis for which there are no effective antibiotics

          -  Asthma complication under treatment

          -  Nasal septum ulcers, nasal surgery, or nasal trauma, which has not healed

          -  Vasomotor rhinitis or eosinophilic rhinitis

          -  Nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic
             rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the
             evaluation of the efficacy of the study drug

          -  History of hypersensitivity to antihistamines or study drug

          -  Currently receiving treatment with another investigational drug or has received an
             investigational drug in the past 3 months

          -  Has started specific desensitization therapy or nonspecific allassotherapy
             (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapies within 90
             days (3 months) before the day of obtaining informed consent

          -  Severe hepatic, renal, cardiac, hematological disease, or other serious coexisting
             diseases and whose general condition is poor

          -  History of malignancy or clinically important hematological disorder

          -  History of severe drug allergy (e.g., anaphylactoid reaction).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2013</study_first_posted>
  <results_first_submitted>July 24, 2014</results_first_submitted>
  <results_first_submitted_qc>July 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Nose Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Cholinergic Antagonists</keyword>
  <keyword>Cholinergic Agents</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Histamine H1 Antagonists, Non-Sedating</keyword>
  <keyword>Histamine H1 Antagonists</keyword>
  <keyword>Histamine Antagonists</keyword>
  <keyword>Histamine Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=4117-200&amp;kw=4117-200&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Desloratadine 5 mg</title>
          <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Desloratadine 10 mg</title>
          <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="202">One randomized participant did not receive study drug.</participants>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="201">One randomized participant did not receive study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Desloratadine 5 mg</title>
          <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Desloratadine 10 mg</title>
          <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="203"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="608"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="13.1"/>
                    <measurement group_id="B2" value="33.7" spread="11.9"/>
                    <measurement group_id="B3" value="34.7" spread="12.6"/>
                    <measurement group_id="B4" value="34.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2</title>
        <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>The Full Analysis Set (FAS) population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2</title>
          <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
          <population>The Full Analysis Set (FAS) population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="2.21" lower_limit="-2.25" upper_limit="-1.67"/>
                    <measurement group_id="O2" value="-1.94" spread="2.21" lower_limit="-2.23" upper_limit="-1.65"/>
                    <measurement group_id="O3" value="-1.87" spread="2.34" lower_limit="-2.16" upper_limit="-1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.661</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in Least Squares (LS) Means</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.707</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE)</title>
        <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who experienced an AE, regardless of causality or severity, was summarized.</description>
        <time_frame>Up to Week 4</time_frame>
        <population>The All-Subjects-as-Treated (ASaT) population consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE)</title>
          <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who experienced an AE, regardless of causality or severity, was summarized.</description>
          <population>The All-Subjects-as-Treated (ASaT) population consisted of all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
        <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who discontinued study drug, whether permanently or temporarily, due to an AE was summarized.</description>
        <time_frame>Up to Week 2</time_frame>
        <population>The ASaT population consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
          <description>An AE is defined as any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE. The number of participants who discontinued study drug, whether permanently or temporarily, due to an AE was summarized.</description>
          <population>The ASaT population consisted of all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1</title>
        <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
        <time_frame>Baseline and Day 3, Week 1</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Day 3 and Week 1</title>
          <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). The TNSS is the sum of the 4 nasal symptom sub-scores. TNSS scores could range from 0 to 12, with a higher score indicating more frequent/severe nasal symptoms.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for TNSS.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline (BL) at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="2.05" lower_limit="-1.38" upper_limit="-0.86"/>
                    <measurement group_id="O2" value="-1.11" spread="2.02" lower_limit="-1.37" upper_limit="-0.85"/>
                    <measurement group_id="O3" value="-0.63" spread="2.03" lower_limit="-0.89" upper_limit="-0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="2.41" lower_limit="-1.68" upper_limit="-1.09"/>
                    <measurement group_id="O2" value="-1.39" spread="2.28" lower_limit="-1.69" upper_limit="-1.10"/>
                    <measurement group_id="O3" value="-1.48" spread="2.32" lower_limit="-1.78" upper_limit="-1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Day 3</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Day 3</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.569</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Week 1</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in TNSS at Week 1</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator</title>
        <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attackes; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores could range from 0 to 3, with a higher nasal symptom sub-score indicating more frequent/severe nasal symptoms.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal symptom sub-scores as assessed by the investigator.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nasal Symptom Sub-Scores Assessed by the Investigator</title>
          <description>The investigator interviewed and examined participants to evaluate for nasal symptoms of: sneezing (daily frequency of attackes; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Nasal symptom sub-scores could range from 0 to 3, with a higher nasal symptom sub-score indicating more frequent/severe nasal symptoms.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal symptom sub-scores as assessed by the investigator.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.75" lower_limit="-0.30" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.29" spread="0.67" lower_limit="-0.38" upper_limit="-0.20"/>
                    <measurement group_id="O3" value="-0.13" spread="0.65" lower_limit="-0.21" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.78" lower_limit="-0.36" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.36" spread="0.75" lower_limit="-0.45" upper_limit="-0.27"/>
                    <measurement group_id="O3" value="-0.38" spread="0.76" lower_limit="-0.47" upper_limit="-0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.74" lower_limit="-0.52" upper_limit="-0.35"/>
                    <measurement group_id="O2" value="-0.51" spread="0.69" lower_limit="-0.59" upper_limit="-0.42"/>
                    <measurement group_id="O3" value="-0.40" spread="0.73" lower_limit="-0.49" upper_limit="-0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.66" lower_limit="-0.47" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.32" spread="0.73" lower_limit="-0.41" upper_limit="-0.22"/>
                    <measurement group_id="O3" value="-0.24" spread="0.74" lower_limit="-0.33" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.77" lower_limit="-0.49" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-0.38" spread="0.83" lower_limit="-0.48" upper_limit="-0.28"/>
                    <measurement group_id="O3" value="-0.44" spread="0.78" lower_limit="-0.54" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.73" lower_limit="-0.67" upper_limit="-0.47"/>
                    <measurement group_id="O2" value="-0.53" spread="0.83" lower_limit="-0.63" upper_limit="-0.43"/>
                    <measurement group_id="O3" value="-0.56" spread="0.83" lower_limit="-0.66" upper_limit="-0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.68" lower_limit="-0.30" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.17" spread="0.68" lower_limit="-0.26" upper_limit="-0.09"/>
                    <measurement group_id="O3" value="-0.13" spread="0.65" lower_limit="-0.22" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.81" lower_limit="-0.38" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.22" spread="0.70" lower_limit="-0.32" upper_limit="-0.13"/>
                    <measurement group_id="O3" value="-0.32" spread="0.73" lower_limit="-0.42" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.78" lower_limit="-0.43" upper_limit="-0.23"/>
                    <measurement group_id="O2" value="-0.33" spread="0.75" lower_limit="-0.43" upper_limit="-0.23"/>
                    <measurement group_id="O3" value="-0.37" spread="0.77" lower_limit="-0.47" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.79" lower_limit="-0.42" upper_limit="-0.22"/>
                    <measurement group_id="O2" value="-0.33" spread="0.82" lower_limit="-0.43" upper_limit="-0.23"/>
                    <measurement group_id="O3" value="-0.15" spread="0.80" lower_limit="-0.25" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.84" lower_limit="-0.55" upper_limit="-0.33"/>
                    <measurement group_id="O2" value="-0.44" spread="0.88" lower_limit="-0.55" upper_limit="-0.34"/>
                    <measurement group_id="O3" value="-0.35" spread="0.88" lower_limit="-0.45" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.91" lower_limit="-0.74" upper_limit="-0.53"/>
                    <measurement group_id="O2" value="-0.58" spread="0.86" lower_limit="-0.68" upper_limit="-0.48"/>
                    <measurement group_id="O3" value="-0.52" spread="0.84" lower_limit="-0.62" upper_limit="-0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.547</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Sneezing Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Sneezing Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.895</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Rhinorrhea Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.627</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Rhinorrhea Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.535</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Nasal Congestion Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Nasal Congestion Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.119</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Nasal Itching Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Nasal Itching Nasal Symptom Sub-Score at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nasal Finding Score Assessed by the Investigator</title>
        <description>The investigator conducted rhinoscopic examinations on participants to evaluate: swelling of inferior nasal concha mucosa (INCM) (score of 0=none to 3=middle nasal concha is not visible), coloring of inferior nasal concha mucosa (INCM) (score of 0=normal to 3=pale), and nasal discharge production (NDP) (score of 0=none to 3=congesting). The score for each nasal finding component could range from 0 to 3, with a higher score indicating more severe symptoms.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal finding score.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nasal Finding Score Assessed by the Investigator</title>
          <description>The investigator conducted rhinoscopic examinations on participants to evaluate: swelling of inferior nasal concha mucosa (INCM) (score of 0=none to 3=middle nasal concha is not visible), coloring of inferior nasal concha mucosa (INCM) (score of 0=normal to 3=pale), and nasal discharge production (NDP) (score of 0=none to 3=congesting). The score for each nasal finding component could range from 0 to 3, with a higher score indicating more severe symptoms.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for nasal finding score.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swelling of INCM: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.70" lower_limit="-0.32" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-0.17" spread="0.68" lower_limit="-0.26" upper_limit="-0.08"/>
                    <measurement group_id="O3" value="-0.13" spread="0.71" lower_limit="-0.22" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling of INCM: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.71" lower_limit="-0.44" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-0.31" spread="0.69" lower_limit="-0.40" upper_limit="-0.21"/>
                    <measurement group_id="O3" value="-0.34" spread="0.78" lower_limit="-0.43" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling of INCM: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.74" lower_limit="-0.48" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.34" spread="0.71" lower_limit="-0.44" upper_limit="-0.24"/>
                    <measurement group_id="O3" value="-0.32" spread="0.82" lower_limit="-0.41" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloring of INCM: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.86" lower_limit="-0.37" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="-0.26" spread="0.79" lower_limit="-0.36" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.26" spread="0.81" lower_limit="-0.36" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloring of INCM: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.88" lower_limit="-0.47" upper_limit="-0.24"/>
                    <measurement group_id="O2" value="-0.38" spread="0.89" lower_limit="-0.49" upper_limit="-0.27"/>
                    <measurement group_id="O3" value="-0.40" spread="0.91" lower_limit="-0.51" upper_limit="-0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloring of INCM: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.97" lower_limit="-0.60" upper_limit="-0.36"/>
                    <measurement group_id="O2" value="-0.48" spread="0.85" lower_limit="-0.60" upper_limit="-0.37"/>
                    <measurement group_id="O3" value="-0.45" spread="0.96" lower_limit="-0.57" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDP: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.76" lower_limit="-0.32" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-0.24" spread="0.75" lower_limit="-0.32" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.18" spread="0.65" lower_limit="-0.27" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDP: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.75" lower_limit="-0.42" upper_limit="-0.24"/>
                    <measurement group_id="O2" value="-0.36" spread="0.75" lower_limit="-0.45" upper_limit="-0.26"/>
                    <measurement group_id="O3" value="-0.41" spread="0.75" lower_limit="-0.50" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NDP: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.71" lower_limit="-0.51" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-0.38" spread="0.76" lower_limit="-0.48" upper_limit="-0.29"/>
                    <measurement group_id="O3" value="-0.44" spread="0.76" lower_limit="-0.54" upper_limit="-0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Swelling of INCM at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.714</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Swelling of INCM at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.725</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Coloring of INCM at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Coloring of INCM at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in NDP at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in NDP at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eye Symptom Score Assessed by the Investigator</title>
        <description>The investigator interviewed and examined participants for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for eye symptom score as assessed by the investigator.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye Symptom Score Assessed by the Investigator</title>
          <description>The investigator interviewed and examined participants for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for eye symptom score as assessed by the investigator.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.76" lower_limit="-0.27" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-0.24" spread="0.71" lower_limit="-0.34" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.13" spread="0.74" lower_limit="-0.22" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.76" lower_limit="-0.38" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.35" spread="0.76" lower_limit="-0.44" upper_limit="-0.25"/>
                    <measurement group_id="O3" value="-0.26" spread="0.83" lower_limit="-0.36" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.84" lower_limit="-0.48" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.44" spread="0.77" lower_limit="-0.54" upper_limit="-0.34"/>
                    <measurement group_id="O3" value="-0.37" spread="0.79" lower_limit="-0.46" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.849</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Eye Symptom Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.260</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change From Baseline in Eye Symptom Score at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator</title>
        <description>The investigator comprehensively evaluated participants on global improvement according to 5 grades: 1=remarkably improved, 2= moderately improved, 3=slightly improved, 4=unchanged, and 5=aggravated. The number of participants who were evaluated as remarkably improved and moderately improved was calculated.</description>
        <time_frame>Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for global improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate-to-Remarkable Improvement in Global Improvement Assessed by the Investigator</title>
          <description>The investigator comprehensively evaluated participants on global improvement according to 5 grades: 1=remarkably improved, 2= moderately improved, 3=slightly improved, 4=unchanged, and 5=aggravated. The number of participants who were evaluated as remarkably improved and moderately improved was calculated.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for global improvement.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 (n=199, 201, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=200, 203, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=200, 203, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.340</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic model with global improvement rate as response variable and treatment, age strata, and severity as factors</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.826</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.558</ci_lower_limit>
            <ci_upper_limit>1.223</ci_upper_limit>
            <estimate_desc>Difference in the number of participants with moderate or remarkable improvement at Week 2. An odds ratio &gt;1 is in favor of the first group of the pairwise comparison.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic model with global improvement rate as response variable and treatment, age strata, and severity as factors</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.510</ci_lower_limit>
            <ci_upper_limit>1.116</ci_upper_limit>
            <estimate_desc>Difference in the number of participants with moderate or remarkable improvement at Week 2. An odds ratio &gt;1 is in favor of the first group of the pairwise comparison.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator</title>
        <description>The investigator interviewed participants at Baseline, Day 3, Week 1 and Week 2 to evaluate interference with daily activities according to the following scale: 0=none, 1=nasal symptom interferes with daily activities from time to time (+), 2=between 1 and 3 (++), and 3=nasal symtom interferes with daily activity often (+++). Interference with daily activities scores could range from 0 to 3, with a higher score indicating greater interference with daily activities.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for interference with daily activities.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator</title>
          <description>The investigator interviewed participants at Baseline, Day 3, Week 1 and Week 2 to evaluate interference with daily activities according to the following scale: 0=none, 1=nasal symptom interferes with daily activities from time to time (+), 2=between 1 and 3 (++), and 3=nasal symtom interferes with daily activity often (+++). Interference with daily activities scores could range from 0 to 3, with a higher score indicating greater interference with daily activities.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for interference with daily activities.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.63" lower_limit="-0.26" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-0.19" spread="0.58" lower_limit="-0.27" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.07" spread="0.62" lower_limit="-0.15" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.69" lower_limit="-0.30" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.21" spread="0.68" lower_limit="-0.29" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.20" spread="0.64" lower_limit="-0.28" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.73" lower_limit="-0.34" upper_limit="-0.16"/>
                    <measurement group_id="O2" value="-0.29" spread="0.69" lower_limit="-0.38" upper_limit="-0.20"/>
                    <measurement group_id="O3" value="-0.27" spread="0.71" lower_limit="-0.36" upper_limit="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.705</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Interference with Daily Activities at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.782</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Interference with Daily Activities at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries</title>
        <description>Participants evaluated themselves in their daily allergy diaries for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Each nasal symptom sub-score could range from 0 to 3, with a higher sub-score indicating more frequent/severe nasal symptoms.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated nasal symptom score.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nasal Symptom Sub-Scores Reported in Participant Diaries</title>
          <description>Participants evaluated themselves in their daily allergy diaries for nasal symptoms of: sneezing (daily frequency of attacks; score of 0=less than 1 time to 3=11+ times), rhinorrhea (daily frequency of blowing nose; score of 0=less than 1 time to 3=11+ times), nasal congestion (score of 0=less than nasal blockage without oral breathing to 3=severe nasal blockage causing prolonged oral breathing in a day), and nasal itching (score of 0=none to 3=nose is itchy, requiring frequent rubbing or blowing nose). Each nasal symptom sub-score could range from 0 to 3, with a higher sub-score indicating more frequent/severe nasal symptoms.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated nasal symptom score.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sneezing: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.72" lower_limit="-0.36" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.32" spread="0.76" lower_limit="-0.41" upper_limit="-0.23"/>
                    <measurement group_id="O3" value="-0.23" spread="0.79" lower_limit="-0.32" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.72" lower_limit="-0.48" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-0.40" spread="0.84" lower_limit="-0.49" upper_limit="-0.30"/>
                    <measurement group_id="O3" value="-0.30" spread="0.75" lower_limit="-0.39" upper_limit="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.81" lower_limit="-0.54" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-0.45" spread="0.86" lower_limit="-0.55" upper_limit="-0.35"/>
                    <measurement group_id="O3" value="-0.33" spread="0.81" lower_limit="-0.44" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.76" lower_limit="-0.30" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-0.29" spread="0.74" lower_limit="-0.39" upper_limit="-0.19"/>
                    <measurement group_id="O3" value="-0.17" spread="0.80" lower_limit="-0.27" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.81" lower_limit="-0.39" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.36" spread="0.81" lower_limit="-0.46" upper_limit="-0.26"/>
                    <measurement group_id="O3" value="-0.34" spread="0.84" lower_limit="-0.44" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinorrhea: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.85" lower_limit="-0.45" upper_limit="-0.22"/>
                    <measurement group_id="O2" value="-0.38" spread="0.86" lower_limit="-0.50" upper_limit="-0.27"/>
                    <measurement group_id="O3" value="-0.45" spread="0.88" lower_limit="-0.57" upper_limit="-0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.71" lower_limit="-0.28" upper_limit="-0.09"/>
                    <measurement group_id="O2" value="-0.17" spread="0.73" lower_limit="-0.27" upper_limit="-0.08"/>
                    <measurement group_id="O3" value="-0.18" spread="0.75" lower_limit="-0.28" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.69" lower_limit="-0.33" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.24" spread="0.79" lower_limit="-0.34" upper_limit="-0.14"/>
                    <measurement group_id="O3" value="-0.25" spread="0.83" lower_limit="-0.35" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.76" lower_limit="-034" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-0.26" spread="0.88" lower_limit="-0.37" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.32" spread="0.78" lower_limit="-0.43" upper_limit="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.76" lower_limit="-0.39" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.35" spread="0.85" lower_limit="-0.45" upper_limit="-0.25"/>
                    <measurement group_id="O3" value="-0.22" spread="0.77" lower_limit="-0.33" upper_limit="-0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.88" lower_limit="-0.51" upper_limit="-0.30"/>
                    <measurement group_id="O2" value="-0.42" spread="0.80" lower_limit="-0.53" upper_limit="-0.32"/>
                    <measurement group_id="O3" value="-0.39" spread="0.87" lower_limit="-0.50" upper_limit="-0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching: Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.92" lower_limit="-0.64" upper_limit="-0.40"/>
                    <measurement group_id="O2" value="-0.47" spread="0.90" lower_limit="-0.59" upper_limit="-0.36"/>
                    <measurement group_id="O3" value="-0.44" spread="0.87" lower_limit="-0.56" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Sneezing at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Sneezing at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.27</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Rhinorrhea at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Rhinorrhea at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.285</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Nasal Congestion at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Nasal Congestion at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Nasal Itching at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Nasal Itching at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eye Symptom Score Reported in Participant Diaries</title>
        <description>Participants evaluated themselves in their daily allergy diaries for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
        <time_frame>Baseline and Day 3, Week 1, Week 2</time_frame>
        <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated eye symptom score.</population>
        <group_list>
          <group group_id="O1">
            <title>Desloratadine 5 mg</title>
            <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Desloratadine 10 mg</title>
            <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eye Symptom Score Reported in Participant Diaries</title>
          <description>Participants evaluated themselves in their daily allergy diaries for eye (itching) symptoms (score of 0=none to 3=eye is itchy, requiring frequent rubbing of eye). Eye symptom scores could range from 0 to 3, with a higher score indicating greater eye itchiness.</description>
          <population>The FAS population consisted of all participants who took at least one dose of study drug and had a baseline or at least one post-baseline assessment for participant-rated eye symptom score.</population>
          <units>Score on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.73" lower_limit="-0.38" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.25" spread="0.72" lower_limit="-0.34" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.20" spread="0.83" lower_limit="-0.30" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.82" lower_limit="-0.40" upper_limit="-0.21"/>
                    <measurement group_id="O2" value="-0.33" spread="0.75" lower_limit="-0.43" upper_limit="-0.24"/>
                    <measurement group_id="O3" value="-0.26" spread="0.80" lower_limit="-0.35" upper_limit="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.80" lower_limit="-0.44" upper_limit="-0.22"/>
                    <measurement group_id="O2" value="-0.35" spread="0.82" lower_limit="-0.45" upper_limit="-0.24"/>
                    <measurement group_id="O3" value="-0.27" spread="0.84" lower_limit="-0.38" upper_limit="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Eye Symptom Score at Week 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model with terms for visit, visit-by-treatment, visit-by-age strata, visit-by-severity interactions; visit treated as a categorical variable</method_desc>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
            <estimate_desc>Difference in LS Means for Change from Baseline in Eye Symptom Score at Week 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 weeks after last dose of study drug (up to 4 weeks)</time_frame>
      <desc>The population consisted of all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Desloratadine 5 mg</title>
          <description>Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Desloratadine 10 mg</title>
          <description>Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants receive two placebo tablets orally once daily for up to 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasphopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

